AMHD — HLK Biotec Holding Share Price
Last trade - 00:00- $0.00m
- $0.42m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -374.07% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 1995 | 1996 | 1997 | 1998 | 1999 | 2000E | 2001E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
HLK Biotec Holding Group, Inc. is a holding company. The Company operates through its China-based subsidiaries, focused on the health industry, research and development (R&D) of high technology (high-tech) health food, healthcare supplies, and low carbon environmental protection. The Company’s wholly owned subsidiary is HLK(Nanjing) Health Food, Co., Ltd.
Directors
- Last Annual
- June 30th, 1999
- Last Interim
- March 31st, 2000
- Incorporated
- May 13th, 2005
- Public Since
- June 21st, 2001
- No. of Shareholders
- 86
- No. of Employees
- 6
- Sector
- Renewable Energy
- Industry
- Energy
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 4,624,573
- Address
- 2612 Granby St, NORFOLK, 23517-1426
- Web
- Phone
- +1 6469263568
- Auditors
- Janover Rubinroit & Co
Similar to AMHD
ABCO Energy
Pink Sheets on Nasdaq
Ace Ethanol LLC
Pink Sheets on Nasdaq
Adkins Energy LLC
Pink Sheets on Nasdaq
Advanced Bioenergy LLC
Pink Sheets on Nasdaq
Alternative Energy Development
Pink Sheets on Nasdaq
FAQ
As of Today at 19:10 UTC, shares in HLK Biotec Holding are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in HLK Biotec Holding last closed at $0.00 and the price had moved by +900% over the past 365 days. In terms of relative price strength the HLK Biotec Holding share price has outperformed the S&P500 Index by +763.72% over the past year.
There is no consensus recommendation for this security.
HLK Biotec Holding does not currently pay a dividend.
HLK Biotec Holding does not currently pay a dividend.
HLK Biotec Holding does not currently pay a dividend.
To buy shares in HLK Biotec Holding you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in HLK Biotec Holding had a market capitalisation of $0.00m.
Here are the trading details for HLK Biotec Holding:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: AMHD
Based on an overall assessment of its quality, value and momentum HLK Biotec Holding is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like HLK Biotec Holding. Over the past six months, its share price has outperformed the S&P500 Index by +734.39%.
As of the last closing price of $0.00, shares in HLK Biotec Holding were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The HLK Biotec Holding PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on HLK Biotec Holding's directors